Obesity Is a Chronic Disease: What That Means for GLP-1 Treatment

Obesity is a complex, long-term condition shaped by biology, genetics, environment, sleep, stress, other medicines, access to food and healthcare, and more. Calling it a chronic disease isn't about putting a label on people. It's a way of recognizing that managing it often takes ongoing support, not one heroic burst of willpower.

That framing has been around for a while. The World Obesity Federation described obesity as a "chronic relapsing progressive disease process" in a 2017 position statement. It's still debated how best to define it, though. In 2025, a Lancet Diabetes & Endocrinology commission of 58 experts proposed separating clinical obesity (excess body fat that's already affecting how organs or the body function) from preclinical obesity (excess body fat with health risks but no such effects yet), arguing BMI alone is too blunt a tool. However you define it, the practical message is similar: this deserves real, ongoing medical care.

Why "just try harder" falls short

Body weight is regulated by interconnected systems that control appetite and energy use. After weight loss, those systems push back: hunger can rise and the body needs less energy. That helps explain why many people regain weight and why responses to treatment vary so much.

None of this means habits don't matter. It means habits happen inside a biological and social context, and blaming individuals for that context isn't fair or useful.

Where medication fits

For eligible people, some approved medicines can be part of long-term management. Benefits and risks differ by product, indication and person. A prescription isn't a shortcut around health; it's one tool within a broader plan.

The chronic-disease lens also explains something many people discover the hard way: in the STEP 1 trial extension, adults who stopped semaglutide 2.4 mg regained about two-thirds of the weight they'd lost within a year. That isn't a personal failure. It's similar to what happens when treatment for other long-term conditions, like high blood pressure, stops. (More in what happens when you stop semaglutide.)

Some people benefit a lot from GLP-1 medicines, some struggle with side effects, and some see a smaller response. All of them deserve follow-up and respectful care.

Why a long-term conversation matters

Useful questions to raise with your clinician:

• How will we measure success, beyond the scale?
• What does follow-up look like, and how often?
• How will cost and access be handled if coverage changes?
• What's the plan if I need to pause or stop?
• Which nutrition, activity or behavioral supports fit my life?

Medication shouldn't be treated as a moral failure, or as a guarantee that every health concern will disappear.

Support without shame

In a 2026 JAMA Network Open interview study of 30 US adults who had taken GLP-1 medicines, people described stigma, cost and access barriers, side effects, and highly variable information and support from clinicians as part of their experience. It was a small qualitative study, so it shows what people go through rather than how common each experience is. Still, it's a reminder that listening without judgment makes it easier to raise problems early. We dig into this in being judged for using GLP-1.

If someone chooses medical treatment, that doesn't give anyone else permission to comment on their body or assume they know the whole story.

A chronic-care approach is realistic, not pessimistic. It leaves room for setbacks, adjustments, changing goals and support over time. The question isn't whether someone deserves help. It's which evidence-based options fit their health and circumstances.